User login
Management of Acute Coronary Syndromes in Patients with Diabetes
The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.
Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.
The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.
Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.
The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.
Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
CME: Current Treatment Strategies for Advanced Prostate Cancer
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
2017 MS Highlights: The Year in Review
Transforming the delivery of cardiovascular care: Research and innovation in the Heart & Vascular Institute
Supplement Editor:
Umesh Khot, MD
Contents
Results of the GLAGOV trial
Steven E. Nissen and Stephen J. Nicholls
Trends in cardiovascular risk profiles
Samir Kapadia
Expanding indications for TAVR: The preferred procedure in intermediate-risk patients?
David L. Brown
CABG: A continuing evolution
Faisal Bakaeen
Improving the safety and efficacy of robotically assisted mitral valve surgery
Stephanie Mick
Aortic replacement in cardiac surgery
Eric E. Roselli
Supplement Editor:
Umesh Khot, MD
Contents
Results of the GLAGOV trial
Steven E. Nissen and Stephen J. Nicholls
Trends in cardiovascular risk profiles
Samir Kapadia
Expanding indications for TAVR: The preferred procedure in intermediate-risk patients?
David L. Brown
CABG: A continuing evolution
Faisal Bakaeen
Improving the safety and efficacy of robotically assisted mitral valve surgery
Stephanie Mick
Aortic replacement in cardiac surgery
Eric E. Roselli
Supplement Editor:
Umesh Khot, MD
Contents
Results of the GLAGOV trial
Steven E. Nissen and Stephen J. Nicholls
Trends in cardiovascular risk profiles
Samir Kapadia
Expanding indications for TAVR: The preferred procedure in intermediate-risk patients?
David L. Brown
CABG: A continuing evolution
Faisal Bakaeen
Improving the safety and efficacy of robotically assisted mitral valve surgery
Stephanie Mick
Aortic replacement in cardiac surgery
Eric E. Roselli
Challenges and advances in cardiovascular disease
Supplement Editor:
Maan A. Fares, MD
Contents
Introduction: Challenges and advances in cardiovascular disease
Maan A. Fares
Cardiac amyloidosis: An update on diagnosis and treatment
Joseph P. Donnelly and Mazen Hanna
Management of coronary chronic total occlusion
Jaikirshan Khatri, Mouin Abdallah, and Stephen Ellis
Update on the management of venous thromboembolism
John R. Bartholomew
Cardiac implantable electronic device infection
Cameron T. Lambert and Khaldoun G. Tarakji
Lung transplant: Candidates for referral and the waiting list
Kenneth R. McCurry and Marie M. Budev
Supplement Editor:
Maan A. Fares, MD
Contents
Introduction: Challenges and advances in cardiovascular disease
Maan A. Fares
Cardiac amyloidosis: An update on diagnosis and treatment
Joseph P. Donnelly and Mazen Hanna
Management of coronary chronic total occlusion
Jaikirshan Khatri, Mouin Abdallah, and Stephen Ellis
Update on the management of venous thromboembolism
John R. Bartholomew
Cardiac implantable electronic device infection
Cameron T. Lambert and Khaldoun G. Tarakji
Lung transplant: Candidates for referral and the waiting list
Kenneth R. McCurry and Marie M. Budev
Supplement Editor:
Maan A. Fares, MD
Contents
Introduction: Challenges and advances in cardiovascular disease
Maan A. Fares
Cardiac amyloidosis: An update on diagnosis and treatment
Joseph P. Donnelly and Mazen Hanna
Management of coronary chronic total occlusion
Jaikirshan Khatri, Mouin Abdallah, and Stephen Ellis
Update on the management of venous thromboembolism
John R. Bartholomew
Cardiac implantable electronic device infection
Cameron T. Lambert and Khaldoun G. Tarakji
Lung transplant: Candidates for referral and the waiting list
Kenneth R. McCurry and Marie M. Budev
Modern Day Laboring
Click here to read the supplement
Modern Day Laboring
Induction of Labor for Low-Risk Women: Is 39 the New 41?
Rohan D’Souza, MD, MSc, MRCOG; Errol R. Norwitz, MD, PhD, MBA
Cervical Ripening in Alternative Settings: Balancing Logistics and Patient Care
Julian N. Robinson, MD; Sarah E. Little, MD
Click here to read the supplement
Modern Day Laboring
Induction of Labor for Low-Risk Women: Is 39 the New 41?
Rohan D’Souza, MD, MSc, MRCOG; Errol R. Norwitz, MD, PhD, MBA
Cervical Ripening in Alternative Settings: Balancing Logistics and Patient Care
Julian N. Robinson, MD; Sarah E. Little, MD
Click here to read the supplement
Modern Day Laboring
Induction of Labor for Low-Risk Women: Is 39 the New 41?
Rohan D’Souza, MD, MSc, MRCOG; Errol R. Norwitz, MD, PhD, MBA
Cervical Ripening in Alternative Settings: Balancing Logistics and Patient Care
Julian N. Robinson, MD; Sarah E. Little, MD
Highlights From the 7th Joint ECTRIMS‑ACTRIMS Meeting
Pediatric Vaccines & Infectious Diseases: Fall 2017
An editorial supplement to Pediatric News.
Articles Include:
- The perpetual challenge of emerging infections
- Teen vaccines: Where are we now, and how can we go further?
- Parental reasons for HPV nonvaccination are shifting
- Make HIV testing of adolescents routine
Faculty:
Michael E. Pichichero, M.D.
Dr. Pichichero, a specialist in pediatric infectious diseases, is director of the Research Institute, Rochester (N.Y.) General Hospital. He is also a pediatrician at Legacy Pediatrics in Rochester. He is an ID Consult columnist for Pediatric News. Dr. Pichichero said that in the past 3 years he has received research funding from Sanofi Pasteur and Merck for investigator-initiated research for vaccine-related research, but not specifically relating to any of the vaccines and topics included in this supplement..
©Copyright 2017, by Frontline Medical Communications Inc. All rights reserved.
An editorial supplement to Pediatric News.
Articles Include:
- The perpetual challenge of emerging infections
- Teen vaccines: Where are we now, and how can we go further?
- Parental reasons for HPV nonvaccination are shifting
- Make HIV testing of adolescents routine
Faculty:
Michael E. Pichichero, M.D.
Dr. Pichichero, a specialist in pediatric infectious diseases, is director of the Research Institute, Rochester (N.Y.) General Hospital. He is also a pediatrician at Legacy Pediatrics in Rochester. He is an ID Consult columnist for Pediatric News. Dr. Pichichero said that in the past 3 years he has received research funding from Sanofi Pasteur and Merck for investigator-initiated research for vaccine-related research, but not specifically relating to any of the vaccines and topics included in this supplement..
©Copyright 2017, by Frontline Medical Communications Inc. All rights reserved.
An editorial supplement to Pediatric News.
Articles Include:
- The perpetual challenge of emerging infections
- Teen vaccines: Where are we now, and how can we go further?
- Parental reasons for HPV nonvaccination are shifting
- Make HIV testing of adolescents routine
Faculty:
Michael E. Pichichero, M.D.
Dr. Pichichero, a specialist in pediatric infectious diseases, is director of the Research Institute, Rochester (N.Y.) General Hospital. He is also a pediatrician at Legacy Pediatrics in Rochester. He is an ID Consult columnist for Pediatric News. Dr. Pichichero said that in the past 3 years he has received research funding from Sanofi Pasteur and Merck for investigator-initiated research for vaccine-related research, but not specifically relating to any of the vaccines and topics included in this supplement..
©Copyright 2017, by Frontline Medical Communications Inc. All rights reserved.